Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen Inc. (BIIB) is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to evaluate the effects of felzartamab on proteinuria in patients with immunoglobulin A nephropathy (IgAN), a condition that causes protein leakage into urine due to kidney damage. The significance lies in potentially improving kidney function and patient outcomes.
The intervention being tested is felzartamab, administered via intravenous infusions. It is designed to reduce proteinuria and improve kidney function in IgAN patients.
The study employs a randomized, parallel intervention model with quadruple masking, meaning neither participants nor those administering the treatment know who receives the drug or placebo. The primary goal is treatment-focused, assessing the efficacy of felzartamab.
The study began on May 8, 2025, with primary completion expected approximately 24 weeks later, followed by an 80-week follow-up. The last update was submitted on August 11, 2025, indicating ongoing recruitment and progress.
This clinical update could influence Biogen’s stock performance positively if felzartamab proves effective, as it would enhance Biogen’s portfolio in nephrology. Investor sentiment may strengthen, especially if competitors lack similar advancements in IgAN treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.